A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSwNP

Change in tight junction expression (Occludin, ZO -1, -2, -3 claudin-1, -4, -7) between baseline, 12 weeks and 24 weeks of add-on treatment evaluated with RTq-PCR and with immunohistochemistry (IHC), Look at the change in mucosal explant integrity between baseline, 12 weeks, and 24 weeks of add on treatment with Dupilumab by means of Ussing Chambers., Change in gene expression profiling between baseline, 12 weeks and 24 weeks of add on treatment with Dupilumab by bulk RNA sequencing.